Half-Year 2022 Financial and Clinical Trials Update
Crenezumab (RG7412)
Humanized monoclonal antibody targeting all forms of Ab
Indication
Phase/study
Alzheimer's prevention initiative (API) Colombia
Phase II
Cognition study
# of patients
N=252
ARM A: PSEN1 E280A mutation carriers receive crenezumab SC or IV
ARM B: PSEN1 E280A mutation carriers receive placebo
Design
▪ ARM C: non-mutation carriers receive placebo
Primary endpoint
Status
▪ Change on Alzheimer's Prevention Initiative (API) Composite Cognitive Test total score at 260 weeks treatment
Annualized rate of change in an Episodic Memory Measure: Free and Cued Selective Reminding Task (FCSRT)
FPI Q4 2013
▪ Recruitment completed Q1 2017
Study did not meet its co-primary endpoints Q2 2022
CT Identifier
In collaboration with AC Immune
Ab-amyloid-beta; SC-Subcutaneous; IV=Intravenous
NCT01998841
143
Roche
NeuroscienceView entire presentation